Sunmin Lee

Institut Pasteur Korea — South Korea

Medicine · Health Sciences

38h-index6.8kcitations244works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(56), Chronic Myeloid Leukemia Treatments(40), Renal cell carcinoma treatment(37), Bladder and Urothelial Cancer Treatments(37), Heat shock proteins research(35)

Publications244 total

Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Figure S3 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Emulsion adjuvant-induced uric acid release modulates optimal immunogenicity by targeting dendritic cells and B cells 3384
The Journal of Immunology·2025Open Access
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer
2025Open Access
Supplementary File 1: Table 1 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary Figure S4 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary File 3: Table 3 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Data from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary file 5: Table 5 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary File 4: Table 4 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary Figure S1 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary Legends from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary Figure S2 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary Figure S5 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
Supplementary Figure S3 from Mitochondrial HSP90 Paralog TRAP1 Deletion Drives Glutamine Addiction in Tumor Cells via Destablization of the Cys/Glu Antiporter SLC7A11/xCT
2025Open Access
page 1 of 13Next →

Frequent Co-authors

Jane B. Trepel(49), Len Neckers(17), Min-Jung Lee(17), Seth M. Steinberg(9), Yusuke Tomita(9), Akira Yuno(7), Kristin Beebe(7), William D. Figg(7), Min-Jung Lee(6), James L. Gulley(6), Yunjin Jung(5), William L. Dahut(5), Leonard Μ. Neckers(5), Jennifer S. Isaacs(4), Maria J. Merino(4), W. Marston Linehan(4), Fatima Karzai(4), Ravi A. Madan(4), Anish Thomas(4), Shinji Tsutsumi(4)